Alyeska Investment Group’s Aligos Therapeutics ALGS Stock Holding History

Alyeska Investment Group’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.38M	Hold	412,000	–	–	0.01%	562
2026 Q1	$3.06M	Hold	412,000	–	–	0.01%	526
2025 Q4	$3.84M	Hold	412,000	–	–	0.01%	483
2025 Q3	$4.04M	Hold	412,000	–	–	0.01%	470
2025 Q2	$2.97M	Hold	412,000	–	–	0.01%	466
2025 Q1	$3.4M	Buy	+412,000	New	+$9.03M	0.01%	389
2024 Q3	–	Sell	-11,369	Closed	-$99.5K	–	520
2024 Q2	$99.5K	Buy	+11,369	New	+$200K	﹤0.01%	540
2024 Q1	–	Sell	-115,289	Closed	-$2.3M	–	455
2023 Q4	$1.91M	Buy	+115,289	New	+$1.98M	0.01%	375
2021 Q2	–	Sell	-600	Closed	-$341K	–	701
2021 Q1	$341K	Hold	600	–	–	﹤0.01%	692
2020 Q4	$415K	Buy	+600	New	+$292K	0.01%	456

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group's ALGS Position: Q2 2026 in Review

Alyeska Investment Group held its Aligos Therapeutics (ALGS) position steady in Q2 2026 at 412,000 shares worth $2.38M. The position accounts for 0.01% of the portfolio, ranked #562.

Alyeska Investment Group first reported a position in ALGS in Q4 2020 and has held it in 10 quarters since. The position peaked at $4.04M in Q3 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Alyeska Investment Group held 412,000 shares of Aligos Therapeutics worth $2.38M as of Q2 2026.
Alyeska Investment Group left its Aligos Therapeutics share count unchanged in Q2 2026.
Aligos Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #562 holding.
Alyeska Investment Group first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 10 quarters since.
Alyeska Investment Group's Aligos Therapeutics position peaked at $4.04M in Q3 2025.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.